A Randomised, Single-blind, Placebo-controlled Trial to Investigate Safety, Tolerability, and Pharmacokinetics of Single Rising Doses of BI 1815368 Administered as Oral Solution to Healthy Male Subjects (SRD Part), and a Randomised, Open-label, Single-dose, Three-way Cross-over Part Investigating Relative Bioavailability of BI 1815368 as Tablet Versus Oral Solution and Tablet With and Without Food in Healthy Male Subjects (BA Part)
Latest Information Update: 21 Oct 2022
Price :
$35 *
At a glance
- Drugs BI 1815368 (Primary) ; BI 1815368 (Primary)
- Indications Unspecified
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 19 Oct 2022 Status changed from active, no longer recruiting to completed.
- 05 Oct 2022 Status changed from recruiting to active, no longer recruiting.
- 15 Jun 2022 Status changed from not yet recruiting to recruiting.